Enlivex Therapeutics Ltd. (ENLV) Financials
ENLV Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2025 | 2.3 billion | 392.1 million |
| Sept. 30, 2025 | 20.9 million | 3.5 million |
| June 30, 2025 | 22.6 million | 3.5 million |
| March 31, 2025 | 24.0 million | 3.4 million |
ENLV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2025 | -2.9 million | 915000 |
| Sept. 30, 2025 | -2.3 million | 280000 |
| June 30, 2025 | -1.2 million | 295000 |
| March 31, 2025 | -4.7 million | 293000 |
ENLV Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| Dec. 31, 2025 | 1.2 billion |
| Sept. 30, 2025 | -2.2 million |
| June 30, 2025 | -1.9 million |
| March 31, 2025 | -3.5 million |
ENLV Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2025 | 5.9 million | - | 383000 |
| Sept. 30, 2025 | 18.3 million | - | 701000 |
| June 30, 2025 | 19.5 million | - | 480000 |
| March 31, 2025 | 20.6 million | - | 503000 |
ENLV Shares Outstanding
ENLV Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2025 | 9383 | 3.0 million | 2.8 million | - |
| Sept. 30, 2025 | 23554 | 1.5 million | 992000 | - |
| June 30, 2025 | 7000 | 2.1 million | 937000 | - |
| March 31, 2025 | 32000 | 2.6 million | 954000 | - |
ENLV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2025 | - | 76000 |
| Sept. 30, 2025 | - | 81000 |
| June 30, 2025 | - | 85000 |
| March 31, 2025 | - | 90000 |
ENLV
Price: $0.67
52 week price:
Earnings Per Share: 25.48 USD
P/E Ratio: 0.04
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: Israel
Volume: 21300
Market Capitalization: 20.7 million